(Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and mAbxience (“mAbxience”) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its ...

Teens often spend hours daily watching videos online, but parents should consider how the content affects their well-being ...

Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, today announced the successful first close of its Series B ...

Celltrion announced Tuesday that its biosimilars Stoboclo and Osenvelt, referencing bone disease treatments Prolia and Xgeva (denosumab), have received marketing approval from the US Food and Drug ...

Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved STOBOCLO® (CT-P41, denosumab-bmwo) ...

Amneal Pharmaceuticals (AMRX) “announced that the FDA has accepted for review its Biologics Licensing Application for two proposed denosumab ...

February brought policy updates and several biosimilar approvals, including the first FDA approval for an insulin aspart biosimilar.

Women with osteoporosis have at least a 50% chance of reaching their target bone mineral density at 3 years if they have a ...

Women's Health Therapeutics Market Rising Awareness and Government Initiatives Drive Growth AUSTIN, TX, UNITED STATES, February 28, 202 ...

In this article, we explore how aging impacts the musculoskeletal system and share expert-backed prevention tips to help you ...

Osteoporosis, often called a silent disease, weakens bones and increases the risk of fractures, making it a leading cause of ...

The FDA has approved the BLA for Ospomyv™ and Xbryk™, biosimilars to Prolia (denosumab) and Xgeva (denosumab), respectively.